Home > Formulary : Adult > Recent Decisions > 2021 >
Decisions 20th July 2021
At the meeting on the 20th July the following decisions were agreed
New Drug Requests
Approved
Cefiderocol (TLS Red)
-
Restricted - microbiology only - see local guidelines
-
For treatment of multidrug resistant aerobic gram-negative infections where there are no other treatment options available
Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Red)
-
For treatment of trichomoniasis vaginalis
Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Amber No SCP)
-
For treatment of bacterial vaginosis
Sanatogen Complete A-Z (TLS Amber No SCP)
- Complete vitamin and mineral supplement to maintain normal levels in intestinal failure patients under the care of the nutrition team
Forceval soluble tablets (TLS Amber No SCP)
- Complete vitamin and mineral supplement to maintain normal levels in intestinal failure patients who have swallowing difficulties under the care of the nutrition team
Shared Care Protocols/TLS changes
New SCPs:
Testosterone (Sustanon and Nebido)
Updated SCPs:
Nil
TLS Changes:
Mycophenolate for neurological indications changed from TLS Red to TLS Amber 3 months pending incorporation into the existing SCP for Mycophenolate.
Other Formulary Decisions:
Budesonide orodispersible tablet (TLS red)
-
For inducing remission of eosinophilic oesophagitis with treatment of up to 12 weeks in line with NICE TA708
Pigmanorm (TLS red)
-
additional information added onto the the formulary to state ‘subject to the Cosmetic Surgery or Treatment Policy’ as well as a link to the Remedy Pathway for cosmetic skin treatments
Dalteparin
-
additional information added onto the Formulary website to state ‘for use where enoxaparin not appropriate for obstetric patients due to allergy/reaction’ in line with current practice.
Sodium aurothiomalate (TLS red)
-
Joint Formulary group agreed to withdraw shared care protocol for sodium aurothiomalate as SCP no longer required and has not been prescribed in the last year.
-
Joint Formulary group agreed to change TLS status to red.
Eplerenone (TLS Amber No SCP)
-
Joint Formulary group agreed to withdraw prescribing guidelines for eplerenone as this has been superseded by new heart failure guidance.
Further Work:
Bempedoic acid with ezetimibe (TLS red)
-
For primary hypercholesterolemia or mixed dyslipidaemia for patients under the care of the Lipid team as per NICE TA694
-
TLS status to be reviewed once NICE TA for inclisiran published and following completion of further work to establish place in pathway.